Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $342.00 Price Target at Scotiabank
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...
Healio6h
Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity
Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
pharmaphorum22h
BridgeBio poised to challenge Pfizer after Attruby approval
including Alnylam, which is hoping to get approval for its vutrisiran candidate next year, and AstraZeneca and Ionis' eplontersen. Both these are already approved to treat ATTR-PN, as Amvuttra and ...